Investor Notice: The Rosen Law Firm Announces Filing Of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA
The Rosen Law Firm today announced that a class action lawsuit has been filed on behalf of purchasers of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA - News) securities during the period from March 30, 2009 through September 17, 2010. The complaint asserts claims against Arena Pharmaceuticals and certain of its officers and directors for violations of the federal securities laws.
To join the class action against Arena Pharmaceuticals, go to the website at http://www.rosenlegal.com or call Laurence Rosen, Esq. or Phillip Kim, Esq. toll-free at 866-767-3653. You may also email firstname.lastname@example.org or email@example.com for information on the class action.
The complaint alleges that the Company misled investors to believe that the pre-clinical and clinical trial data for its developmental drug lorcaserin, or Lorqess, indicate it is a safe therapy for weight management.
On September 14, 2010, the FDA disclosed that lorcaserin caused cancer in rats in certain preclinical studies.As a result of this adverse news, Arena shares declined from a close of $6.85 per share on September 13, 2010, to close at $4.13 per share on September 14, a decline of $2.71 per share or approximately 40%. On September 16, 2010, the Wall Street Journal reported a federal advisory panel rejected lorcaserin. On September 17, 2010, Arena shares declined an additional $1.99 per share or approximately 47%, causing investors substantial losses. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER. If you wish to join the class action or to discuss your ability to recover your investment losses, please contact Laurence Rosen, Esq. or Phillip Kim, Esq. of The Rosen Law Firm toll-free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com. The Rosen Law Firm concentrates its practice on investor securities litigation, representing investors throughout the world.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV